1. Пирогов А. Л. Гепарин-индуцированная тромбоцитопения при сердечно-сосудистых вмешательствах. Механизмы развития, диагностики и методы коррекции. Комплексные проблемы сердечно-сосудистых заболеваний. 2014; 4: 96–98. Pirоgov A. L. Heparin inducent thrombocytohenia in cardiovascular surgery. Pathogenesis, diagnostics and correction methods. Complex Issues of Cardiovascular Diseases. 2014; 4: 96–98.
2. Чарная М. А., Дементьева И. И., Морозов Ю. А., Гла¬ дышева В. Г., Исаева А. М. «Искусственная» гипокоагуляция у больных с гепарин-индуцированными тромбоцитопениями (обзор литературы). Часть 1. Кардиология и сердечнососудистая хирургия. 2013; 2: 87–89. Часть 2. Кардиология и сердечно-сосудистая хирургия. 2013; 3: 90–91. Charnaia M. A., Dementeva I. I., Morozov Iu. A., Gladysheva V. G., Isaeva A. M. Artificial hypocoagulation in with Heparin-induced thrombocytohenias (literature review). Part I. Cardiology & cardiovascular surgery. 2013; 2: 87–89. Part II. Cardiology & cardiovascular sergery. 2013; 3: 90–91.
3. Greinacher A., Warkentin T. E. Heparin-induced thrombocytopenia. N. Y: Marcel Dekker. 2004; 627.
4. Mar A. W., Dixon B., Ibrahim K., Parkin J. D. Skin necrosis following subcutaneous heparin injection. Australas. J. Dermatol. 1995; 36 (4): 201–203.
5. Warkentin T. E., Roberts T. S., Hirsch J., Kelton J. G. Heparininduced skin lesions and other unusual sequelae of the heparininduced-thrombocytopenia syndrome: a nested cohort study. Chest. 2005; 127 (5): 1857–1861.
6. Ling E., Warkentin T. E. Intraoperative heparin flushes and subsequent acute heparin-induced thrombocytopenia. Anesthesiology. 1998; 89 (6): 1567–1569.
7. Warkentin T. E., Kelton J. G. A 14-year study of heparininduced thrombocytopenia. Am. J. Med. 1996; 101 (5): 502–507.
8. Xiao Z., Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with low molecular weight heparin and with direct thrombin inhibitor. Circulation. 1998; 97: 251–256.
9. WarkentinT.E.CookR. J. et al. Anti-PF 4/heparin antiboby formation postorhopedic surhery thromboprophylaxis: the role of nondrug risk factor and evidence for a stoichiometrybased model of immunization. J. Thromb. Haemost. 2010; 8 (3): 505–511.
10. Montalescot G., Collet J. P., Lison L. et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J. Am. Coll. Cardiol. 2000; 36: 110–1115.
11. Sciulli T. M., Mauro V. F. Pharmacology and clinical use of bivalirudin. Ann. Pharmacother. 2002 Jun; 36 (6): 1028– 1041. Review.
12. Maraganore J. M., Bourdon P., Jablonski J., Ramachandran K. L., Fenton J. W. 2nd. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors ofthrombin. Biochemistry. 1990 Jul; 31; 29 (30): 7095–7101.
13. Ганюков В. И., Протопопов А. В. Медикаментозное сопровождение чрезкожных коронарных вмешательств. Новосибирск. 2014; 19–20, 47–48, 59–61. Ganiukov V. I., Protopopov A. V. Medicamentoznoe soprovogdenie chrezkognyx koronarnyx vmeshatelstv. Novosibirsk. 2014; 19–20, 47–48, 59–61.
14. Dyke C. M., Smedira N. G., Koster A., Aronson S., Harry L., McCarthy II et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery withcardiopulmonary bypass: The EVOLUTION-ON study. The Journal of Thoracic and Cardiovascular Surgery. 131 (3): 534–539.
15. Кoster A., Dyke C. M., Aldea G. et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the СHOOSE-ON trial. Ann. Thorac. Surg. 2007; 83 (2): 572–577.
16. Smedira N. G., Dyke C. M., Koster A., Jurmann M., Bhatia D. S. et al. Anticoagulation with bivalirudin for offpump coronary arterybypass grafting: The results of the EVOLUTION-OFF study. The Journal of Thoracic and Cardiovascular Surgery. March 2006; 688–692.
17. Dyke C. M., Кoster A., Aldea G. et al. Off-pump coronary artery bypass with Bivalirudin for pacients with heparin-induced thrombocytopenia antiplatelet factor four/ heparin antibodies. Ann. Thorac. Surg. 2007; 84 (3): 836–839.
18. Riess F. C., Poetzsch B., Madlener K. et al. Recombinant hirudin as an alternative for cardiopulmonary bypass anticoagulation: a randomized, prospective, and heparin-controlled pilot study. Thorac. Cardiovasc. Surg. 2007; 55 (4): 233–238.
19. Кoster A., Hansen R., Kuppe H. et al. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with previous with heparin-induced thrombocytopenia typeII6 1 year experience in 57 patients. J. Cardiothorac. Vasc. Anesth. 2000; 14 (3): 243–248.
